Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT00326911. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Open-Label Study of Cetuximab and Bevacizumab Alone or in Combination With Fixed-Dose Rate Gemcitabine as First-Line Therapy of Patients With Metastatic Adenocarcinoma of the Pancreas
Study identification
- NCT ID
- NCT00326911
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Interventions
- cetuximab Biological
- bevacizumab Biological
- gemcitabine Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Sep 30, 2008
- Completion
- Nov 30, 2008
- Last update posted
- May 24, 2011
2006 – 2008
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Jonesboro | Arkansas | 72401 | — |
| ImClone Investigational Site | San Francisco | California | 94115 | — |
| ImClone Investigational Site | Stamford | Connecticut | 06902 | — |
| ImClone Investigational Site | Miami | Florida | 33176 | — |
| ImClone Investigational Site | Orlando | Florida | 32804 | — |
| ImClone Investigational Site | Orlando | Florida | 32806 | — |
| ImClone Investigational Site | Atlanta | Georgia | 30309 | — |
| ImClone Investigational Site | Augusta | Georgia | 30901 | — |
| ImClone Investigational Site | Marietta | Georgia | 30060 | — |
| ImClone Investigational Site | Metairie | Louisiana | 70006 | — |
| ImClone Investigational Site | Billings | Montana | 59101 | — |
| ImClone Investigational Site | Concord | North Carolina | 28025 | — |
| ImClone Investigational Site | Philadelphia | Pennsylvania | 19106 | — |
| ImClone Investigational Site | Charleston | South Carolina | 29406 | — |
| ImClone Investigational Site | Arlington | Texas | 76012 | — |
| ImClone Investigational Site | Dallas | Texas | 75230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00326911, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 24, 2011 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00326911 live on ClinicalTrials.gov.